| 000 | 01683nam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223025926.0 | ||
| 008 | 090915s2009 ua dh f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aPh.D | ||
| 099 | _aCai01.08.08.Ph.D.2009.Ah.S | ||
| 100 | 0 | _aAhmed Abdelrahman Mohamed Ahmed Elashmawy | |
| 245 | 1 | 0 |
_aStudy on diltiazem hydrochloride controlled-release dosage forms / _cAhmed Abdelrahman M. A. Elashmawy ; Supervised Nadia M. Mursi , Rania M. Badr Eldeen |
| 246 | 1 | 5 | _aدراسة على الاشكال الصيدلية المنضبطة الانطلاق لعقار هيدروكلوريد الديلتيازيم |
| 260 |
_aCairo : _bAhmed Abdelrahman Mohamed Ahmed Elashmawy , _c2009 |
||
| 300 |
_a258P. : _bcharts , facsimiles ; _c25cm |
||
| 502 | _aThesis (Ph.D.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics | ||
| 520 | _aDiltiazem hydrochloride is a calcium channel blocker drug and widely prescribed at relatively high doses for the treatment of hypertension and angina. It is a freely water- soluble drug. The short half- life of diltiazem ranging from 3 to 5 hours requires multipe daily drug dosage in order to maintain adequate plasma concentrations | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aControlled- Release | |
| 653 | 4 | _aDiltiazem Hydrochloride | |
| 653 | 4 | _aGel- Matrix Tablets | |
| 700 | 0 |
_aNadia Mohamed Mursi , _eSupervisor |
|
| 700 | 0 |
_aRania Mohamed Badr Eldeen , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 902 | _a1 | ||
| 905 |
_aFatma _eCataloger |
||
| 905 |
_aNazla _eRevisor |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c23700 _d23700 |
||